

A practical guide for providers on helping patients locate Insulin Degludec (Tresiba) during the 2026 shortage, with tools and workflows.
When patients on Insulin Degludec (Tresiba) call your office unable to fill their prescription, time matters. Basal insulin isn't a medication that can wait — especially for patients with type 1 diabetes or those with type 2 diabetes on intensive regimens. This guide gives you and your staff practical tools and workflows to help patients locate Insulin Degludec quickly and, when necessary, transition to alternatives safely.
For background on the current shortage, see: Insulin Degludec Shortage: What Providers Need to Know in 2026.
Before assuming a supply issue, confirm the details:
MedFinder for Providers is a free tool designed to help clinical staff locate medications in short supply. Here's how to use it for Insulin Degludec:
This can be handled by clinical support staff and takes just a few minutes. Consider making this part of your standard workflow for shortage-affected medications.
Novo Nordisk's provider support line can assist with:
Call 1-888-668-6444 or visit NovoCare.com. NovoCare representatives can sometimes identify stock at pharmacies not visible through standard channels.
Mail-order pharmacies typically maintain larger insulin inventories and are less affected by local supply fluctuations. If your patient's insurance supports mail-order, this is often the most reliable option during shortages. Common mail-order pharmacies include Express Scripts, CVS Caremark, and OptumRx.
Some specialty pharmacies focus on diabetes medications and may have dedicated Insulin Degludec stock. These pharmacies can also handle complex insurance authorizations.
If your practice is affiliated with a hospital system, the hospital outpatient pharmacy may have Insulin Degludec available through different distribution channels than retail pharmacies.
For patients seen at 340B-eligible entities (FQHCs, certain hospitals), 340B contract pharmacies may have access to Insulin Degludec at discounted pricing and through different supply allocations.
If Insulin Degludec cannot be located immediately, consider these bridging strategies:
When Insulin Degludec is truly unavailable and no pharmacy has stock, switching is the right call. The most common alternatives:
| Alternative | Conversion | Key Consideration |
|---|---|---|
| Insulin Glargine U-100 (Lantus/Basaglar/Semglee) | 1:1 unit-for-unit | Must dose at consistent time daily; slightly more variability |
| Insulin Glargine U-300 (Toujeo) | May need 10-15% dose increase | Closest PK match to degludec; flat profile |
| Insulin Detemir (Levemir) | 1:1, often BID dosing | Shorter duration; consider only if glargine unavailable |
See our detailed clinical switching guide: Insulin Degludec Shortage: What Providers Need to Know.
Rather than reacting to each patient call, consider setting up proactive systems:
Patients may be anxious about the shortage, especially those who have been well-controlled on Insulin Degludec for years. Key reassurances:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.